Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén

doi:10.1016/S0140-6736(04)16104-7

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Lancet. 2004 May 1;363(9419):1439-41. doi: 10.1016/S0140-6736(04)16104-7.

Authors

Katarina Le Blanc¹, Ida Rasmusson, Berit Sundberg, Cecilia Götherström, Moustapha Hassan, Mehmet Uzunel, Olle Ringdén

Affiliation

¹ Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden. Katarina.Leblanc@medhs.ki.se

PMID: 15121408
DOI: 10.1016/S0140-6736(04)16104-7

Abstract

Adult bone-marrow-derived mesenchymal stem cells are immunosuppressive and prolong the rejection of mismatched skin grafts in animals. We transplanted haploidentical mesenchymal stem cells in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver. Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Adult
Child
Chromosomes, Human, X
Chromosomes, Human, Y
Female
Graft vs Host Disease / therapy*
Haploidy
Humans
Immunosuppression Therapy
In Situ Hybridization, Fluorescence
Intestinal Mucosa / ultrastructure
Lymphocyte Culture Test, Mixed
Male
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells / immunology
Transplantation Chimera
Transplantation, Homologous